Physician profile
John P Odonnell
NPI 1891795175
$4,389.82
in general payments reported to CMS, 2019-2025
33 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,411 · 2022: $1,077 · 2023: $765 · 2024: $791 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.45 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $589.34 | 2021-2025 | |
| Novo Nordisk INC | $415.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $326.01 | 2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.14 | 2021-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $212.31 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $173.27 | 2022-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $140.43 | 2022-2023 | |
| Amgen INC. | $114.54 | 2021-2023 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $89.19 | 2021-2022 | |
| Dexcom, INC. | $82.94 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $80.05 | 2021-2022 | |
| Exact Sciences Corporation | $66.83 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $65.38 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $61.29 | 2024 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $54.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $53.40 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $52.53 | 2021 | |
| Insulet Corporation | $47.02 | 2023-2024 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $45.33 | 2021 | |
| Ironwood Pharmaceuticals, INC | $41.12 | 2022-2023 | Linzess |
| Supernus Pharmaceuticals, INC. | $38.30 | 2021 | |
| Pfizer INC. | $36.95 | 2022-2023 | |
| Medtronic, INC. | $34.65 | 2023 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $30.16 | 2022-2025 | Rexulti |
| Boston Scientific Corporation | $24.41 | 2022 | |
| Philips North America LLC | $23.07 | 2025 | Extended Holter |
| Exeltis, USA INC. | $15.89 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.71 | 2021 | |
| Hikma Pharmaceuticals USA | $14.71 | 2021 | |
| Horizon Therapeutics Plc | $14.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2021 | |
| Agile Therapeutics, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Odonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.